March 10, 2022
462,781
15,935
4,216
4.35%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
25:08Now PlayingFree PDFs of my two text books, direct link for downloads,
Physiology book in hard copy
Looking at the evidence
Florida
Children with underlying conditions are the best candidates for the COVID-19 vaccine.
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (NEJM)
(Delta time data)
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (NEJM)
N = 2,268, (phase 2 clinical trial)
NIH covid SeroHub
Reduced vaccine efficacy in with omicron
Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant
New York State Department of Health
December 13, 2021 to January 30, 2022
Aged 12 – 17, n = 852,384 fully-vaccinated
Aged, 5 – 11 years, n = 365,502 fully-vaccinated
Risk of myocarditis due to the COVID-19 vaccine
Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021(JAMA, 2022)
(70.7 per million doses of the BNT162b2 vaccine)
in adolescent males aged 16 to 17 years
(105.9 per million doses of the BNT162b2 vaccine)
in young men aged 18 to 24 years
(52.4 per million doses of BNT162b2)
(56.3 per million doses of
mRNA-1273 )
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.